NUKUTE OY

Their core work

Nukute is a Finnish medical technology SME specializing in non-invasive screening and remote monitoring of sleep disorders, particularly sleep apnea. Their core product, developed under the PREDESA project, is a device that enables remote detection and personalized therapy management for sleeping disorders without requiring hospital-based polysomnography. They successfully progressed through the EU SME Instrument from a feasibility study to a full commercial pilot across Europe, indicating a product with real market readiness. Their work sits at the intersection of consumer health technology, digital health, and clinical diagnostics.

What they specialise in

How they've shifted over time

Nukute's H2020 participation spans only 2016 to 2020 and covers a single product trajectory rather than a shift in domain. Their Phase 1 project in 2016 was a focused feasibility study for a sleep apnea screening device, while the Phase 2 project from 2017 onward expanded the scope to a full EU pilot including personalized therapy — not just detection. The progression reflects product maturation rather than a pivot in expertise: from proving the concept works to proving it can scale commercially across European markets.

Nukute appears to be a single-product company that used EU funding to mature one technology from concept to commercial pilot — future collaboration would most likely center on distribution partnerships, clinical validation, or integration with digital health platforms rather than new R&D directions.

How they like to work

Nukute has acted exclusively as project coordinator across both H2020 projects, which is typical of the SME Instrument funding scheme — a program designed for individual companies rather than consortia. No external partners are recorded in the data, meaning they have operated as a self-contained unit, likely managing any subcontractors or clinical partners outside formal EU consortium structures. Working with them likely means engaging directly with the founding team on technology licensing, clinical trials, or distribution agreements rather than joining a research consortium.

Nukute's recorded H2020 network shows zero formal consortium partners across two projects, consistent with the SME Instrument model where individual companies receive funding directly. Their geographic reach beyond Finland is not documented in the project metadata, though the Phase 2 project describes an EU pilot — suggesting operational activity across multiple countries not captured in the partnership data.

What sets them apart

Nukute is one of very few SMEs that completed the full SME Instrument Phase 1 → Phase 2 journey for a sleep disorder screening product, which signals that independent EU evaluators judged their technology credible enough to fund at both proof-of-concept and commercial pilot stages. Their focus on non-invasive, remote-use technology for sleep apnea directly addresses a major unmet need — most sleep apnea diagnosis still requires expensive in-clinic overnight studies. For a consortium or business partner, they bring a validated medical device concept with EU-backed commercial evidence rather than pure research outputs.

Highlights from their portfolio

• PREDESA
  The Phase 2 PREDESA project (€1.75M) is notable as one of the largest SME Instrument Phase 2 awards in the digital health space, covering a full EU commercial pilot for non-invasive sleep disorder screening — a rare example of a Finnish SME taking a single medical device concept all the way through the EU funding ladder.
• PREDESA
  The Phase 1 PREDESA feasibility study (2016) is noteworthy as the validated starting point that unlocked Phase 2 funding, confirming the technology passed EU-level technical and market scrutiny before any significant investment was committed.